Yidan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yidan Wang has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Wei Xu
McArdle Laboratory for Cancer Research University of Wisconsin–Madison Madison Wisconsin USA
14 shared publications - Eui-Jun Kim
University of Wisconsin–Madison 1 McArdle Laboratory for Cancer Research Madison, Wisconsin
12 shared publications - Jingjing Zhou
University of Wisconsin–Madison 1 McArdle Laboratory for Cancer Research Madison, Wisconsin
12 shared publications - Lingjun Li
University of Wisconsin-Madison
12 shared publications - Peng Liu
University of Wisconsin–Madison 2 Carbone Comprehensive Cancer Center Madison, Wisconsin
12 shared publications - Aussie Suzuki
McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, USA
11 shared publications
Latest Publications
- 14 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF22
Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer
Patients with hormone receptor–positive/HER2-positive (HR+/HER2+) breast cancer represent a historically underrecognized subgroup demonstrating poor response to combined endocrine and HER2-targeted therapies. In this study, using single-cell transcriptomic and epigenomic sequencing of estrogen receptor–positive (ER+)/HER2+ models, we identified BRD8, an acetyl-lysine reader in the EP400 histone acetyltransferase complex, as a critical mediator of ER/HER2 signaling cross-talk. BRD8 expression rapidly increased following anti-HER2 treatment, whereas its depletion disrupted ER–HER2 interaction and enhanced drug sensitivity. Single-nucleus assay for transposase-accessible chromatin using sequencing revealed that chromatin regions opening after anti-HER2 treatment were enriched for ER, FOX, and ETS transcription factor motifs, coinciding with BRD8-dependent gene activation through EP400-mediated acetylated H2AZ deposition. BRD8 regulated ER-dependent and ER-independent growth pathways, and depletion of BRD8 abolished neratinib-induced ER activation and restored drug sensitivity in resistant cells. A three-gene BRD8 signature successfully predicted anti-HER2 therapy response in two human clinical trials. Together, these findings establish BRD8 as both a predictive biomarker for anti-HER2 response and a therapeutic target to overcome resistance in HR+/HER2+ breast cancer. Significance: Multiomic single-cell profiling of breast cancer identified BRD8 as a critical mediator of resistance to HER2-targeted therapies that enables ER-HER2 cross-talk and serves as a predictive biomarker for treatment response.
- 14 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF22
Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer
Patients with hormone receptor–positive/HER2-positive (HR+/HER2+) breast cancer represent a historically underrecognized subgroup demonstrating poor response to combined endocrine and HER2-targeted therapies. In this study, using single-cell transcriptomic and epigenomic sequencing of estrogen receptor–positive (ER+)/HER2+ models, we identified BRD8, an acetyl-lysine reader in the EP400 histone acetyltransferase complex, as a critical mediator of ER/HER2 signaling cross-talk. BRD8 expression rapidly increased following anti-HER2 treatment, whereas its depletion disrupted ER–HER2 interaction and enhanced drug sensitivity. Single-nucleus assay for transposase-accessible chromatin using sequencing revealed that chromatin regions opening after anti-HER2 treatment were enriched for ER, FOX, and ETS transcription factor motifs, coinciding with BRD8-dependent gene activation through EP400-mediated acetylated H2AZ deposition. BRD8 regulated ER-dependent and ER-independent growth pathways, and depletion of BRD8 abolished neratinib-induced ER activation and restored drug sensitivity in resistant cells. A three-gene BRD8 signature successfully predicted anti-HER2 therapy response in two human clinical trials. Together, these findings establish BRD8 as both a predictive biomarker for anti-HER2 response and a therapeutic target to overcome resistance in HR+/HER2+ breast cancer. Significance: Multiomic single-cell profiling of breast cancer identified BRD8 as a critical mediator of resistance to HER2-targeted therapies that enables ER-HER2 cross-talk and serves as a predictive biomarker for treatment response.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Reverse expression patterns of CARM1 and MAP2K4 in breast cancer subtypes and CARM1-mediated MAP2K4 methylation potentiates the downstream JNK activation
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Reverse expression patterns of CARM1 and MAP2K4 in breast cancer subtypes and CARM1-mediated MAP2K4 methylation potentiates the downstream JNK activation
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Raw RPPA data, related to Figure 1
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Raw RPPA data, related to Figure 1
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Methylation of MAP2K4 promotes MDA-MB-468 cell proliferation and migration
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Methylation of MAP2K4 promotes MDA-MB-468 cell proliferation and migration
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
CARM1i and PI3Ki elicited a synergistic anti-growth effect MDA-MB-231, SUM159 and Cal-51 TNBC cell lines
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
CARM1i and PI3Ki elicited a synergistic anti-growth effect MDA-MB-231, SUM159 and Cal-51 TNBC cell lines
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Subcellular localization of CARM1, total MAP2K4 and me-MAP2K4 in MDA-MB-231 and Cal-51 parental cells and the corresponding CARM1KO cells.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Subcellular localization of CARM1, total MAP2K4 and me-MAP2K4 in MDA-MB-231 and Cal-51 parental cells and the corresponding CARM1KO cells.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Treatment with EZM2302 increases CARM1 and PRMT1 levels, and the list of proteins affected by BKM120, TP-064, or both, and the basal AKT activation status in various breast cancer cell lines.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Treatment with EZM2302 increases CARM1 and PRMT1 levels, and the list of proteins affected by BKM120, TP-064, or both, and the basal AKT activation status in various breast cancer cell lines.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
The list of proteins whose levels are affected by treatment with TP-064, BKM120, or both in Fig. 1B.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
The list of proteins whose levels are affected by treatment with TP-064, BKM120, or both in Fig. 1B.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
CARM1i and PI3Ki synergistically inhibit the growth of a patient-derived xenograft organoid (PDxO)
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
CARM1i and PI3Ki synergistically inhibit the growth of a patient-derived xenograft organoid (PDxO)
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
PI3Ki and CARM1i combinational treatment strongly inhibited the growth of PDXs and 4T1 tumors in vivoorganoid (PDxO)
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
PI3Ki and CARM1i combinational treatment strongly inhibited the growth of PDXs and 4T1 tumors in vivoorganoid (PDxO)